Reports / Nephrology Reports / Market Dynamix: Lupus and Lupus Nephritis US
Market Dynamix: Lupus and Lupus Nephritis US
Market Dynamix™: Lupus and Lupus Nephritis (US) combines qualitative feedback from leading opinion leaders and other stakeholders with large scale quantitative feedback of “in the trenches” nephrologists (n=101) and rheumatologists (n=100). In addition, select data points from RealWorld Dynamix: SLE, a large-scale patient chart audit of patients with moderate to severe SLE (n=1,032) completed by the managing rheumatologist is included.
Learn more about Market Dynamix™ reports here.
- What is the comparative level of unmet need for new products to treat lupus and lupus nephritis? Which lupus manifestations are the most challenging to manage?
- What does current treatment looks like for patients with lupus and lupus nephritis, including off-label regimens? What percentage of patients are on chronic corticosteroids?
- Among current SLE patients, what percentage are currently treated with Benlysta? What percentage are candidates but not on drug? What are the barriers to increased use of Benlysta?
- What is the clinical status of current patients? How many have had lupus flares in the past year? How severe were the flares?
- Which pipeline agents are rheumatologists and nephrologists most familiar with for SLE (rheumatologists) and LN (nephrologists)? Which MOAs are most appealing?
- What percentage of SLE patients would be candidates for Lilly’s Olumiant and Janssen’s Stelara, assuming these agents win FDA approval?
- What percentage of LN patients would likely be treated with Benlysta assuming it receives an indication for LN?
- What is nephrologists’ reaction to the profile of voclosporin, a novel calcineurin inhibitor in development for the treatment of LN?
- Who do rheumatologists and nephrologists consider to be the key opinion leaders for SLE and LN?
- What do these experts think about pipeline agents and where they may fall in the treatment paradigm?
Off-label rituximab, HP Acthar gel
Development for SLE:
Olumiant (Lilly), Stelara (Janssen), filgotinib (Gilead/Galapagos), Atacicept (EMD Serono), Dapirolizumab (UCB/Biogen), Evobrutinib (EMD Serono), Fenebrutinib (Roche), Lupuzor (ImmuPharma), BMS-986165 (BMS), BIIB059 (Biogen), CC-220 (Celgene), anifrolumab (AstraZeneca)
Development for lupus nephritis:
Benlysta (GSK), voclosporin (Aurinia), anifrolumab (AstraZeneca), obinituzumab (Roche), BI-655604 (Boehringer Ingelheim), CFZ553 (Novartis), mizoribine (Asahi Kasei Pharma)
Janssen’s INVOKANA (canagliflozin) Gets Boost Over Competitors with FDA Approval for Diabetic Kidney Disease and a Newly Minted Collaboration with Renal Giant, Vifor Pharma – November 25, 2019
US Nephrologists Are Optimistic About the Potential for Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) for the Treatment of Renal Anemia – August 1, 2019